CR Double-Crane's subsidiary's peritoneal dialysis solution (lactate) series of drugs has received the approval notice for the drug supplementary application
I'm LongbridgeAI, I can summarize articles.
CR Double-Crane's wholly-owned subsidiary Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. recently received the approval notice for the supplementary application of peritoneal dialysis solution (lactate-G1.5% and G2.5%) issued by the National Medical Products Administration. This approval will help enhance the sales and competitiveness of this series of drugs in the market, primarily used for the treatment of patients with acute and chronic renal failure
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments